Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain
CompletedNCT01990729
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To study the safety and efficacy of ARTRA (glucosamine chondroitin sulfate) in the treatment of non-specific low-back pain of lumbosacral localization in ambulatory care.
Study details
- Official title
- Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Non-specific Chronic Low Back Pain of Lumbosacral Localization in Ambulatory Care
- Conditions
- Interventions
- Dietary supplement: ARTRA
- Sponsor
- Unipharm, Inc.
- Start date
- 2010-07
- Primary completion
- 2013-01
- Sex
- All
- Age range
- from 40 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Russia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Patients aged 40-65 years, inclusively. 2. Pain intensity according to Visual Analogue Scale (VAS) \> 3 points. 3. Duration of back pain \> 12 weeks. 4. Pain reinforcement during movement in lumbar spine. 5. Osteoarthritis, spondylarthrosis, osteochondrosis. 6. Given written Informed consent form for participation in the study. 7. Treatment with ARTRA Exclusion Criteria: 1. History of allergic reactions to chondroprotectors. 2. Participation in another clinical study within 30 days before screening or during this study. 3. Fibromyalgia. 4. Active neoplastic disease, history of neoplastic disease within 3 years before screening. 5. Paget's disease. 6. Degenerative spondylolisthesis. 7. Administration of anticonvulsant, antidepressant, barbiturate, anxiolytic, or muscle relaxant drugs for more than one week prior screening. 8. History of alcohol or drug abuse. 9. Frequent episodes of nausea, dyspepsia, pain in the epigastric region, diarrhea, face and extremities edema, dizziness and headache. 10. History of any disease that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the subject during participation in the study 11. Clinically significant renal disorders. \-
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01990729